How Serious Is Squamous Cell Carcinoma of the Lung?

Squamous cell carcinoma of the lung is a serious and often life-threatening cancer, ranking as the second most common subtype of lung cancer worldwide. In early-stage disease caught before spread, five-year survival sits around 77%, which sounds reasonable until you compare it with the roughly 90% five-year survival for early-stage lung adenocarcinoma, its more common cousin. At the metastatic end of the spectrum, median survival with modern immunotherapy combinations reaches about 16 months. The seriousness of any individual case depends heavily on stage at diagnosis, but several features of squamous cell lung cancer, from where it grows to how it evades screening, make it a particularly challenging disease.

How Common Is Squamous Cell Lung Cancer

Globally in 2020, squamous cell carcinoma accounted for roughly a quarter of all lung cancers in men and about 12% in women. In absolute numbers, that translated to about 351,800 cases in men and 91,000 in women worldwide. Adenocarcinoma has overtaken it as the dominant subtype in most countries, but squamous cell remains the second largest category by a wide margin, ahead of both small-cell and large-cell carcinoma.¹

The sex gap is striking. Age-adjusted incidence rates for squamous cell lung cancer run nearly five times higher in men than in women. That disparity tracks closely with historical smoking patterns, since squamous cell carcinoma has the tightest link of any lung cancer subtype to heavy, prolonged cigarette exposure. As smoking rates have fallen and cigarette design has changed, squamous cell’s share of all lung cancers has been shrinking for decades, a shift discussed further below.

Where It Grows and Why That Matters

Most squamous cell lung cancers arise centrally, in or near the large airways close to the center of the chest. This distinguishes them from adenocarcinomas, which tend to develop in the peripheral lung tissue closer to the chest wall.² That central location carries several consequences that shape the disease’s seriousness.

First, tumors growing inside or adjacent to the major bronchi can physically block the airway. A partially obstructed bronchus leads to recurrent pneumonia, wheezing, and progressive shortness of breath. When the blockage becomes severe, it causes malignant central airway obstruction, a complication that can require emergency bronchoscopic procedures such as laser ablation, electrocautery, or airway stent placement just to allow the patient to breathe.³ In one series of patients who received self-expanding metal stents for airway obstruction, shortness of breath improved substantially in about 88% of cases, and collapsed lung segments re-expanded in all patients who had that complication on presentation.⁴ These interventions are palliative rather than curative, but they can dramatically improve quality of life.

Second, the central location places the tumor near major blood vessels, which raises the risk of serious bleeding. Coughing up blood is one of the classic presenting symptoms of squamous cell lung cancer. In advanced cases treated with combined chemotherapy and radiation, a specific complication called fatal pulmonary hemorrhage can occur when tumor tissue dies rapidly next to fragile irradiated blood vessels. One study found this complication was rare overall (about 2.6% of treated patients) but jumped to over 37% in patients who had tumors contacting major vessels with a large area of contact.⁵

How Diagnosis Works

Distinguishing squamous cell carcinoma from other lung cancer types under the microscope matters because it changes treatment. Pathologists use a panel of protein markers on biopsied tissue to confirm squamous lineage. The markers CK5/6, p40, and p63 all detect squamous differentiation with sensitivities around 93–94%. Current guidelines favor p40 or CK5/6 for routine use because p63 has a lower specificity, meaning it sometimes lights up in adenocarcinomas too.⁶ Getting the subtype right is essential because certain chemotherapy drugs used for adenocarcinoma (like pemetrexed) don’t work well in squamous cell, and some targeted therapies carry different risk profiles depending on histology.

The cancer develops through a well-characterized sequence of tissue changes in the bronchial lining driven by chronic inflammation, typically from years of cigarette smoke. The lining progresses through stages of overgrowth and abnormal remodeling. But this progression is not a one-way street. At any stage, the changes can stall, stay stable for years, or even reverse, which is part of why quitting smoking at any point reduces lung cancer risk.⁷

Survival and Prognosis Compared With Adenocarcinoma

When squamous cell lung cancer is caught at an early, surgically resectable stage, outcomes are meaningful but consistently trail adenocarcinoma. A study comparing the two subtypes after surgery found a five-year overall survival rate of 77% for squamous cell versus 90% for adenocarcinoma. The gap was most pronounced in the earliest stage of disease (stage IA), where adenocarcinoma patients did substantially better. By stages IB and IIA, the survival difference between the two subtypes narrowed and was no longer statistically significant.⁸

An interesting wrinkle: in adenocarcinoma, a larger tumor invasion size predicts worse survival, which fits the intuition that bigger tumors are more dangerous. In squamous cell carcinoma, that relationship was not found, meaning the factors that drive squamous cell prognosis are more complex than tumor size alone. Age and overall health likely play outsized roles, since squamous cell patients tend to be older and have more smoking-related damage to their lungs and cardiovascular systems.

At more advanced stages, especially once the cancer has spread to distant organs, the prognosis becomes grim. Before modern immunotherapy, median survival for metastatic squamous cell lung cancer with chemotherapy alone was about 11 months. The common sites of distant spread include bone, liver, adrenal glands, and brain.⁹

A Feature That Predicts Recurrence

One pathological finding that has emerged as an important prognostic marker is called “spread through air spaces,” or STAS, where tumor cells detach from the main mass and float into the surrounding lung’s tiny air sacs. In squamous cell carcinoma, STAS has been found in roughly a third of surgical specimens.¹⁰ When it is present, patients face significantly higher rates of both recurrence and lung cancer death compared to patients whose tumors lack this feature.¹¹ STAS isn’t something patients can control, but its presence on a surgical pathology report helps oncologists decide how aggressively to pursue follow-up treatment after surgery.

Complications Unique to This Subtype

Beyond the airway obstruction and bleeding risk discussed earlier, squamous cell lung cancer has a notable tendency to cause a metabolic emergency called hypercalcemia of malignancy. This happens because the tumor cells produce a protein that mimics parathyroid hormone, tricking the body into pulling excess calcium out of bones and into the bloodstream. The calcium-sensing receptor on these cancer cells drives this process, stimulating production of the parathyroid-hormone-like protein through a signaling cascade.¹² Symptoms of hypercalcemia include confusion, severe nausea, excessive thirst, and in extreme cases, cardiac arrest. It’s one of the oncologic emergencies that emergency physicians are trained to recognize, and in a patient with no known cancer, it sometimes turns out to be the very first sign that a squamous cell lung cancer exists.

Newer treatments have introduced their own complication risks. When centrally located squamous tumors are treated with combined chemoradiation followed by immunotherapy, the rapid destruction of tumor tissue next to already-damaged blood vessels can trigger catastrophic bleeding. A case report documented fatal hemoptysis in a patient whose squamous cell carcinoma had achieved complete remission after receiving immunotherapy following radiation, likely because the combination caused rapid tumor necrosis within irradiated lung tissue that still had fragile vessels.¹³ This paradox, where effective treatment itself can be dangerous because of where the tumor sits, is part of what makes central squamous cell lung cancer especially challenging to manage.

Why Screening Often Misses It

Low-dose CT screening has been one of the most important advances in lung cancer detection, demonstrated to reduce lung cancer mortality in high-risk populations. But the benefits are not evenly distributed across subtypes. Most screen-detected cancers are peripheral adenocarcinomas, which show up as small nodules in the outer lung that CT scans are well designed to spot. Squamous cell carcinomas, growing centrally near the airways and hilar structures, are harder to see on a low-dose scan that uses no intravenous contrast.¹⁴

A study analyzing central versus peripheral cancers in screening programs found that low-dose CT screening did not demonstrate an improvement in outcomes for central lung cancers, unlike the clear benefit seen for peripheral cancers. The authors flagged this as an important limitation of current screening and called for novel approaches to detect and treat central lung cancers earlier.¹⁵ This means that even people who diligently participate in lung cancer screening programs have a blind spot for the very subtype most tightly linked to smoking. Researchers have been investigating complementary approaches such as sputum-based molecular testing and fluorescence bronchoscopy, though none has yet become standard practice.

How Treatment Has Changed

Surgery remains the cornerstone for squamous cell lung cancer caught before it has spread widely. Because these tumors often involve the central airways, the operations tend to be more complex than for peripheral cancers. Sometimes the surgeon needs to remove an entire lung (pneumonectomy), but newer strategies are shrinking those cases. In one reported case, an 81-year-old man with a centrally located tumor that would have required a pneumonectomy was instead treated with chemotherapy plus immunotherapy before surgery. The pre-operative treatment shrank the tumor enough that a less radical operation could be performed, and the pathology showed a major response with all visible cancer eliminated.¹⁶ This kind of pre-surgical (“neoadjuvant”) approach, combining chemotherapy with immunotherapy, is rapidly becoming standard for eligible patients with locally advanced disease.

For metastatic squamous cell lung cancer, immunotherapy has been the most meaningful advance in years. The landmark KEYNOTE-407 trial showed that adding the immune checkpoint drug pembrolizumab to standard chemotherapy improved median overall survival from about 11.3 months to 15.9 months and nearly doubled the rate of tumor shrinkage.¹⁷ The five-year follow-up of that trial showed that about 18% of patients receiving the immunotherapy combination were still alive at five years, compared with roughly 10% receiving chemotherapy alone.¹⁸ Those numbers are still sobering, but they represent genuine progress for a disease that had little to offer beyond standard chemotherapy a decade ago. The benefit held regardless of how much PD-L1 the tumor expressed, meaning even patients whose tumors had low levels of this biomarker still gained something from the combination.

Occasionally, the response to immunotherapy is dramatic. Case reports describe patients with high PD-L1-expressing squamous cell tumors achieving complete disappearance of all visible cancer on imaging after several cycles of pembrolizumab, with the response lasting years after treatment was stopped.¹⁹ These exceptional responses are not typical, but they illustrate a biological reality: some squamous cell tumors are highly vulnerable to immune-mediated attack. Predicting which patients will have this kind of response remains one of the field’s open questions.

The Molecular Landscape and Targeted Therapy

One frustrating dimension of squamous cell lung cancer is how far behind it lags in targeted therapy compared to adenocarcinoma. Lung adenocarcinomas frequently carry specific driver mutations (like EGFR mutations or ALK rearrangements) that can be matched to highly effective targeted drugs. Squamous cell carcinoma’s molecular profile is different. The most common genetic alteration is a mutation in the TP53 tumor suppressor gene, found in over half of cases, followed by changes in genes like CDKN2A and PIK3CA at lower frequencies. Among copy number changes, amplification of the SOX2 gene occurs in roughly 30% of squamous cell tumors, and amplification of FGFR1 in about 16%.²⁰

TP53 mutations are loss-of-function changes in a protective gene, which makes them hard to target directly with drugs. And TP53 mutations appear to set off a cascade of further genetic instability. Patients with mutated TP53 had about twice the odds of also acquiring changes in SOX2, suggesting these alterations feed off each other.²¹ Clinical trials have explored targeting the FGFR1, PI3K, CDK4/6, and EGFR pathways in squamous cell lung cancer, but so far, no targeted drug has achieved the kind of transformative results seen with EGFR inhibitors in adenocarcinoma.²² This is an active area of research, and the hope is that better understanding of squamous cell biology will eventually yield precision medicine options for this subtype. For now, immunotherapy plus chemotherapy remains the backbone of systemic treatment.

Why Squamous Cell Used to Be the Most Common Lung Cancer

Decades ago, squamous cell carcinoma was the dominant form of lung cancer in many countries. Its gradual displacement by adenocarcinoma is one of the more interesting epidemiological stories in cancer. The leading explanation involves the shift from unfiltered to filtered cigarettes beginning in the mid-twentieth century. The 2014 U.S. Surgeon General’s Report concluded that changes in cigarette design, particularly the addition of ventilated filters that lower machine-measured tar yields, contributed to rising rates of adenocarcinoma.²³

The mechanism seems to be that filtered, lower-tar cigarettes change how smokers inhale. With less tar per puff, smokers compensate by inhaling more deeply, pulling smoke further into the peripheral lung where adenocarcinoma tends to arise. Unfiltered cigarettes delivered more concentrated carcinogens to the central airways, favoring squamous cell development. A Japanese case-control study confirmed this pattern: lifelong filter-cigarette smokers had reduced risk of squamous cell carcinoma compared with unfiltered-cigarette smokers, but the protective effect was smaller for adenocarcinoma. Among younger men, filter-exclusive smokers actually showed increased adenocarcinoma risk alongside decreased squamous cell risk.²⁴

Occupational exposures also play a role in some populations. Among German uranium miners, who were exposed to high levels of radon gas, both squamous cell carcinoma and small-cell carcinoma were associated with higher cumulative radon exposure than adenocarcinoma. When silicosis (scarring from silica dust) was also present, the proportion of squamous cell carcinoma was relatively elevated.²⁵ These findings reinforce that squamous cell carcinoma is tightly connected to chronic irritation and inflammation of the airway lining, whether the irritant is cigarette smoke, radon, or industrial dust.

Radiation for Tumors That Cannot Be Removed

When surgery is not an option, radiation therapy is a primary alternative. For smaller tumors in patients who cannot tolerate surgery, stereotactic body radiation therapy (SBRT) delivers high-dose, precisely targeted radiation over a handful of sessions. This approach works well for peripheral tumors, but for centrally located squamous cell cancers, it gets more complicated. The proximity of the tumor to the airways, heart, and major vessels limits how much radiation can be safely delivered. A study of SBRT for ultra-central tumors (those directly abutting or invading major central structures) found that moderate doses spread over four to six sessions were effective and generally tolerable, but also cautioned that treatment-related death was a possible outcome.²⁶ This is the kind of risk-benefit calculation that oncologists and patients navigate together, weighing the danger of an untreated cancer against the real hazards of treating one in a difficult location.

For locally advanced squamous cell cancers that cannot be surgically removed, the standard approach is concurrent chemotherapy and radiation followed by immunotherapy, a regimen that has extended survival but carries cumulative toxicity. Deciding on the right treatment plan often requires a multidisciplinary team because the central location of these tumors means that surgery, radiation, and systemic therapy each carry unique risks that need to be weighed against each other.